1. Introduction {#S5}
===============

Tuberculosis (TB) and HIV are the two leading causes of death from infectious diseases in resource-limited countries \[[@R1]\], The HIV epidemic has led to a major upsurge in TB cases worldwide, especially in Africa, as people living with HIV (PLHIV) who are infected with TB are much more likely to develop TB disease than those who are HIV-negative. Nigeria, in particular, has about 3.5 million PLHIV, an HIV prevalence of 3.1% among adults aged 15--49 years, and the highest number of AIDS-related deaths in the world \[[@R2]\], In addition, in 2015 the World Health Organization (WHO) ranked it among the six countries that contribute 60% of the world's TB burden \[[@R1]\], The same year, the HIV positivity rate among TB patients with a documented HIV test result was 17% \[[@R1]\].

The updated 2012 WHO strategic framework for TB/HIV collaborative activities highlights specific activities to reduce HIV-associated TB, including intensified TB case finding, isoniazid preventive therapy and TB infection control for PLHIV, as well as provider initiated HIV counseling and testing for TB patients, with early antiretroviral therapy (ART) uptake for co-infected patients \[[@R3]\], Several clinical trials have demonstrated survival benefit due to early initiation of ART among HIV-infected patients with TB, particularly among those with very low CD4 cell counts \[[@R4]--[@R8]\]. Based on this evidence, WHO guidelines recommend that all HIV-positive TB patients receive ART within eight weeks of TB treatment initiation, or within two weeks if profoundly immunosuppressed (CD4\<50cell/μL) \[[@R3]\]

In Nigeria, there has been remarkable progress in the implementation of collaborative TB/HIV activities over the past few years. Guidelines published by the national TB/HIV technical working group of the Federal Ministry of Health (FMOH) prescribed the initiation of all TB/HIV patients on ART, irrespective of CD4 cell count, with timing in line with WHO recommendations \[[@R9]\].

This study aimed to assess uptake of ART among HIV-positive TB patients in Nigeria, the timing of ART initiation in relation to TB treatment, and TB treatment outcomes of co-infected patients. Through in-depth interviews provider perceptions and current practices of patient referral systems were also ascertained. Findings will assist the FMOH and President's Emergency Plan for AIDS Relief (PEPFAR)-funded implementing partners to develop effective interventions to improve access to and quality of TB/HIV care and treatment services in Nigeria. They also establish a baseline for monitoring future progress of TB/HIV programme implementation.

2. Methods {#S6}
==========

Study Design and Sampling {#S7}
-------------------------

This evaluation involved a retrospective review of TB and HIV clinical records for adult TB patients aged 15 years and above who enrolled in all TB Directly Observed Therapy (DOT) facilities in Federal Capital Territory (FCT) and Ogun State between October 1, 2012 and September 30, 2013. Health facility TB registers and additional supplemental TB data sources such as Presumptive TB registers, TB treatment cards, and Local Government Area TB registers were reviewed to determine the total number of TB patients seen in 2013 with an HIV status recorded as positive or unknown. These patients were traced to HIV facilities to ascertain their treatment status and timing of ART initiation relative to TB treatment, using HIV care cards and ART registers. In both states, all PEPFAR-supported ART treatment facilities that were providing ART services as of October 1, 2012 were included. In FCT there were 16 facilities and in Ogun State there were 28.

In-depth interviews were conducted with 333 key health care workers selected randomly across all the study facilities using a semi-structured questionnaire, in order to assess knowledge and practices related to TB/HIV management as well as provider perceptions about the barriers to provision and uptake of ART.

Data Collection and Analysis {#S8}
----------------------------

Data were collected using a specifically designed data abstraction form that captured demographics, TB and HIV treatment, timing of ART, and TB treatment outcome information, following a retrospective review of the existing TB and HIV clinical and program recording and reporting systems. Descriptive statistics, including frequencies and percentages were used to summarize the data, and 95% confidence limits for all statistics were computed, taking into account the design effect resulting from within-clinic correlation. Unadjusted and adjusted odds ratios (ORs and AORs) and 95% confidence intervals (CI) were calculated to describe associations between categorical variables and ART uptake. Multiple logistic regression was used to assess for predictors of timely ART uptake. We defined 'timely ART' per WHO guidelines as ART started within two weeks of TB treatment initiation for patients with a CD4 cell count \<50cells/μL, and within eight weeks for all other cases. For the purposes of the multivariate analysis, we also considered ART initiation to have been timely for patients with a missing CD4 cell count only if it was started within two weeks, presuming that in the absence of a CD4 test the patient should be treated sooner rather than later. SAS 9.3^®^ (SAS Institute, Cary, NC) was used with procedures designed to account for clustered data, such as PROC SURVEYFREQ and PROC SURVEYLOGTSTTC. The in-depth interviews were transcribed, coded, and thematically analyzed.

Ethical Considerations {#S9}
----------------------

The protocol and all supporting data collection tools were reviewed by the United States Centers for Disease Control and Prevention (CDC) Associate Director for Science and the Nigeria Research and Ethics Committee, and was determined as a non-research program evaluation as the study involved the use of routine programmatic data with minimal risk to subjects.

3. Results {#S10}
==========

Baseline Characteristics of Study Participants {#S11}
----------------------------------------------

Data were abstracted from a total of 4,810 TB patients from 44 DOTS sites in FCT and 70 in Ogun State. These were made up of 1,249 TB patients with a positive or unknown HIV status (574 and 675, respectively). Of the HIV-positive TB patients, median age was 36 (interquartile range \[IQR\] 30--43), 308 (54.1%) were female, and median CD4 cell count was 178cells/μL (IQR: 80--298) ([Table 1](#T1){ref-type="table"}). Most of these patients were between ages 25--44 (69.5%), and seen within secondary health care facilities (55.7%). Three hundred and fifty-one (65.9%) accessed DOT at health facilities while 182 (34.2%) had TB treatment supporters for treatment at home. Two hundred and forty six (44.7%) had pulmonary smear-positive TB, 277 (50.4%) had pulmonary smear-negative TB, and 27 (4.9%) had extra-pulmonary TB. The majority of patients were new TB cases (92.9%) ([Table 1](#T1){ref-type="table"}).

Timing of ART Uptake among TB/HIV Co-infected Patients {#S12}
------------------------------------------------------

Among 574 HIV-positive TB patients evaluated, 90 (15.7%, 95% CI: 7.1--24.2) had already started ART before TB treatment, while 256 (44.6%, 95% CI: 35.9--53.3) were not documented to have initiated on ART during the six-month course of TB treatment at all. CD4 cell count was missing for 199 patients (34.7%). Of the 273 patients with a known CD4 cell count greater than or equal to 50cells/μL who were not already on ART when they started TB treatment, 82 (30.0%, 95% CI: 22.4--37.7) started ART within the recommended eight weeks of TB treatment initiation, while 60 (22.0%, 95% CI: 12.4--31.5) started ART during TB treatment but only after eight weeks. Among the 54 patients with a CD4 cell count \<50cells/μL who were not already on ART at the time of TB treatment initiation, only eight (14.8%, 95% CI: 6.6--23.0) commenced ART within the recommended two weeks of TB treatment initiation, and 21 others (38.9%) started ART, but after two weeks had passed. The remaining 25 (46.3%) were not documented to have started ART at all while on TB treatment ([Table 2](#T2){ref-type="table"}). Of these 25, 14 achieved TB cure or treatment completion, three defaulted, three died, four transferred out and one had no TB treatment outcome reported.

Factors Associated with Timely ART Uptake among Co-infected Patients {#S13}
--------------------------------------------------------------------

In our multivariate analysis, CD4 cell count was found to be the only factor associated with Timely ART provision (using the previously stated definition of "timely ART provision"), with AORs of 2.7 (95% CI: 1.4--5.3) and 2.7 (95% CI: 1.2--6.2) for CD4 cell count categories 50--199cells/μL and 200--499/μL, respectively, when compared with having a CD4 cell count less than 50cells/μL ([Table 3](#T3){ref-type="table"}).

TB Treatment Outcomes for HIV-Positive Patients {#S14}
-----------------------------------------------

TB treatment outcome was documented for 558 (97.4%) of patients with a positive HIV status ([Table 1](#T1){ref-type="table"}). Seventy eight percent of patients with a CD4 cell count ≥50cells/μL had documented cure or treatment completion (a positive outcome), compared with 63.2% of those with CD4 cell count \<50cells/μL and 57.2% of those with a missing CD4 cell count. Removing the 41 patients who transferred out, the odds of a positive outcome for patients with a CD4 cell count ≥50cells/μL was 2.6 (95% CI: 1.6--4.3) times that for patients with a missing CD4 cell count, but not significantly higher than for patients with a CD4\<50cells/μL. For patients with documented treatment failure or default, median time to this outcome was 67.0 days (IQR: 43.0--141.1) for the eight patients (11.8%) with CD4\<50/μL, 93.0 days (IQR: 63.0--154.0) for the 30 patients (44.1%) with CD4 ≥50cells/μL, and 72.0 days (IQR: 27.5--119.0) for the 30 patients (44.1%) with a missing CD4 cell count. Median time to death of those who died during follow up was 41 days (IQR: 34.0--53.0) for the six patients (10.0%) with CD4\<50cells/μL, 55.0 days (IQR: 41.0--99.0) for the 22 (36.7%) with CD4≥50cells/μL, and 30.0 days (IQR: 4.0--53.0) for the 32 (53.3%) with a missing CD4 cell count.

Healthcare Worker Perceptions of Barriers to Timely ART Uptake for HIV-Infected TB Patients {#S15}
-------------------------------------------------------------------------------------------

Semi-structured interviews were conducted with 333 health care workers to assess their perceptions and current practices of patient referral between TB and HIV programs and facilities ([Table 4](#T4){ref-type="table"}). Of 312 interviewees that responded to the question on which TB/HIV service delivery model was used in their facility, 125 (40.1%) worked in a facility with an integrated TB/HIV service delivery model. Of 240 respondents, 137 (57.1%) reported having CD4 services available. The preferred mode of referral of patients between HIV and TB services was by escort (40.1%) followed by use of referral slips (38.4%). Most of the staff interviewed (84.4%) reported having TB/HIV guidelines available, however only 59.6% of 285 respondents reported prior training on TB/HIV. Additionally, only 38.8% of 242 respondents reported adhering to recommendations for ART initiation in TB/HIV co-infected patients irrespective of CD4 count, and only 41.9% knew that patients with a CD4 less than 50cells/μL should start ART within two weeks of TB treatment initiation.

Key recommendations from healthcare worker respondents for improving TB/HIV services for patients ranged from capacity building for health care workers (12.4%), proper patient follow up (19.0%), to patient counseling and health education (38.5%).

4. Discussion {#S16}
=============

Our study shows that almost 45% of HIV-positive TB patients (55% ART uptake) were not documented to be started on ART before or during their six-month course of TB treatment, despite WHO and Nigerian guideline recommendations. The study participants were selected from DOTS sites across primary, secondary and tertiary health facilities in Ogun State and FCT, Nigeria. This proportion is much higher than the 67% ART uptake reported by WHO for Nigeria within same study period, and also higher than reported elsewhere in sub-Saharan Africa in settings where TB and HIV services were not integrated, WHO TB Report \[[@R10]--[@R14]\], Possibly, this could indicate poor documentation of ART initiation in charts in our sampled health facilities, or ART initiated after TB treatment completion. Interviewed healthcare workers in this study also identified poor linkage between TB and HIV services as barrier to timely ART initiation for HIV-positive TB patients. To address this problem, the Nigerian FMOH has since introduced TB/HIV referral coordinators within high volume ART sites to support referral linkages between DOTS and ART sites so as to improve service uptake among TB and HIV co-infected patients.

The approximately 85% of our HIV-positive TB patients who were not already on ART at the time of TB treatment initiation -- if they started ART at all during the course of TB treatment -- were not likely to do so within the recommended timeframe. Less than a third of patients with a CD4≥50cell/μL started ART within the recommended eight weeks, and only 15% of those with a CD4\<50cell/μL started within the recommended two weeks. Almost half of this latter, highly immunocompromised group was not reported to start ART at all during TB treatment, even though the majority of them lived and were followed until successful TB treatment or cure, indicating a window of opportunity to start timely ART that was not prematurely cut short due to loss-to-follow-up or death. This is far behind what has been reported in similar settings in Africa \[[@R15]--[@R17]\].

A documented CD4 cell count was missing for 35% of patients. For the more than 40% of health workers interviewed who reported basing their decision to initiate ART on CD4 cell count results, this is problematic. However, this practice is counter to recommended guidelines to begin ART in HIV-positive TB patients irrespective of CD4 cell count, and is likely a major barrier to timely ART uptake. For those that did have a CD4 cell count reported, a CD4 cell count greater or equal to 50cells/μL significantly predicted timely ART, as well as TB treatment completion or cure. The former finding is similar to those from a collaborative analysis of data from South African cohorts, which found that the overall time to starting ART was strongly associated with patient CD4 cell counts \[[@R12]\]. It is important to note that we expected a shorter time to ART initiation for people with lower CD4 counts, and defined "timely ART" differently based on a CD4 cutoff of 50cell/μL; this, while perhaps influencing the likelihood of meeting the expected timeframe, is appropriate based on WHO and Nigerian guidelines. Unfortunately, only 40% of healthcare workers interviewed knew that patients with lower CD4 cell counts should start ART earlier. Clearly, additional training and supportive supervision of health care workers in ART clinics is required.

Overall, almost 70% of co-infected patients had documented TB treatment completion or cure, which reflects the global average \[[@R1]\], Timely ART initiation relative to TB treatment was not significantly associated with TB treatment outcomes at six months. This has been shown elsewhere, although several randomized controlled trials have demonstrated that early ART improves survival for those with very low CD4 cell counts \[[@R5], [@R6], [@R18]--[@R21]\], The odds of a positive TB treatment outcome were, however, more than twice as high for those with CD4 cell counts greater than 50cells/μL than for those with a missing CD4 cell count. Median time to death, treatment failure or default was not significantly different between these groups, indicating that this finding is not simply due to higher rates of death or loss to follow up for those with a missing CD4 cell count.

The key strength of this study was that it assessed routine programmatic data from all types of TB treatment sites, supplemented with in-depth interview with health care workers that provided insights into program challenges and recommendations for improvement. However, some limitations exist. Sites were not nationally representative, patients were not tracked to non-PEPFAR ART facilities and poor documentation in some facilities led to missing data. We were not able to disaggregate findings based on co-located versus stand-alone TB and HIV facilities, and were only able to follow patients for the six-month duration of their TB treatment course to determine ART uptake.

Overall, this assessment demonstrates unacceptably low levels of timely ART uptake among HIV-positive TB patients in Nigeria, and provides important programmatic feedback to the Nigerian FMOH. Fully integrated TB and HIV service delivery, retraining of staff, ensuring adherence to guidelines recommendations, and interventions to strengthen referral systems should be implemented to ensure timely provision of ART to all HIV-positive TB patients in Nigeria, thus reducing morbidity and mortality and advancing efforts to achieve the ambitious 90-90-90 targets.
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###### 

Demographic and Clinical Characteristics of Study Participants

  Variable                                N     \%
  --------------------------------------- ----- ------
                                                
  **Age (N=574)**                               
  15--24                                  49    8.5
  25--34                                  183   31.9
  35--44                                  216   37.6
  45--54                                  96    16.7
  ≥55                                     30    5.2
                                                
  **Gender (N=569)**                            
  Male                                    261   45.9
  Female                                  308   54.1
                                                
  **Baseline CD4 (cells/μL) (N=574)**           
  0--49                                   61    10.6
  50--199                                 147   25.6
  200--499                                141   24.6
  ≥500                                    26    4.5
  Missing                                 199   34.7
                                                
  **TB Facility Type (N=571)**                  
  Primary                                 112   19.6
  Secondary                               318   55.7
  Tertiary                                141   24.7
                                                
  **Type of DOT services (N=533)**              
  Health facility                         351   65.9
  Home (treatment supporter)              182   34.1
                                                
  **TB Disease Classification (N=550)**         
  Pulmonary smear positive                246   44.7
  Pulmonary smear negative                277   50.4
  Extra-pulmonary                         27    4.9
                                                
  **TB Patient Category (N=562)**               
  New                                     522   92.9
  Relapse                                 11    2.0
  Return after default                    3     0.5
  Transfer in                             15    2.7
  Prior treatment failure                 1     0.2
  Other[\*](#TFN1){ref-type="table-fn"}   10    1.8
                                                
  **TB Treatment Outcome (N=558)**              
  Cured                                   115   20.6
  Completed                               274   49.1
  Failure                                 6     1.1
  Default                                 62    11.1
  Died                                    60    10.8
  Transfer out                            41    7.3

TB patient with unknown previous TB treatment history

###### 

Timing of ART Uptake after the Start of TB Treatment Initiation, among Co-infected Patients

  ------------------------------------------------------------------------------------------------------------------------------------
                                      CD4 \<50   CD4 \>=50      CD4 Missing   All Patients                              
  ----------------------------------- ---------- -------------- ------------- -------------- ----- -------------- ----- --------------
  Before TB treatment (Rx)            7          11.5\          41            13.1\          42    21.1\          90    15.7\
                                                 (0.6--22.3)                  (3.3--22.8)          (12.3--29.9)         (7.1--24.2)

  \<2 weeks since TB Rx initiation    8          13.1\          28            8.9\           19    9.5\           55    9.6\
                                                 (5.2--21.0)                  (5.4--12.4)          (5.6--13.5)          (6.9--12.3)

  2--8 weeks since TB Rx initiation   13         21.3\          54            17.2\          21    10.6\          88    15.3\
                                                 (8.7--34.0)                  (12.3--22.1)         (4.8--16.3)          (11.2--19.5)

  \>8 weeks since TB Rx initiation    8          13.1\          560           19.1\          17    8.5\           85    14.8\
                                                 (5.2--21.0)                  (11.1--27.1)         (3.9--13.2)          (9.8--19.8)

  No ART during 6 months TB Rx        25         41.0\          131           41.7\          100   50.3\          256   44.6\
                                                 (25.9--56.0)                 (31.1--52.3)         (37.2--63.3)         (35.9--53.3)

  **TOTAL**                           61                        314                          199                  574   
  ------------------------------------------------------------------------------------------------------------------------------------

###### 

Factors associated with[\*](#TFN2){ref-type="table-fn"} Timely ART provision to HIV-infected TB patients.

  Variable                   N (%)        OR(95% CI)          p-value     AOR(95% CI)         p-value
  -------------------------- ------------ ------------------- ----------- ------------------- -----------
  **Sex**                                                     .2507                           --
  Male                       53 (24.8)    1.29 (0.83--2.00)                                   
  Female                     54 (20.3)    *ref*                                               
  **Age**                                                     **.0220**                       .0795
  15--24                     7 (17.1)     0.44 (0.15--1.27)               0.68 (0.26--1.78)   
  25--34                     31 (19.4)    0.51 (0.24--1.09)               0.59 (0.27--1.29)   
  35--44                     37 (21.0)    0.56 (0.28--1.14)               0.62 (0.31--1.28)   
  45--54                     25 (31.7)    0.98 (0.46--2.10)               1.10 (0.48--2.50)   
  ≥ 55                       9 (32.1)     *ref*                           *ref*               
  **TB Patient Category**                                     .0853                           .2011
  New                        104 (23.2)   1.81 (0.92--3.57)               1.69 (0.76--3.76)   
  Other                      4 (14.3)     *ref*                                               
  **TB Classification**                                       .8448                           --
  Pulmonary smear +          48 (22.6)    1.32 (0.36--4.83)                                   
  Pulmonary smear −          55 (23.7)    1.40 (0.44--4.45)                                   
  Extra-pulmonary            4 (18.2)     *ref*                                               
  **Baseline CD4**                                            **.0010**                       **.0012**
  \<50/μL                    8 (14.8)     *ref*                           *ref*               
  50--199/μL                 41 (32.3)    2.74 (1.41--5.31)               2.67 (1.36--5.22)   
  200--499/μL                40 (32.8)    2.81 (1.31--6.02)               2.74 (1.22--6.15)   
  ≥500/μL                    1 (4.2)      0.25 (0.03--1.91)               0.25 (0.03--1.87)   
  Missing                    19 (12.1)    0.79 (0.40--1.57)               0.79 (0.39--1.61)   
  **Type of DOT services**                                    .9512                           --
  Health Facility            66 (23.0)    0.98 (0.56--1.74)                                   
  Home                       38 (23.3)    *ref*                                               
  **TB Outcome**                                              .2588                           --
  Cured or Completed         82 (24.8)    1.57 (0.67--3.69)                                   
  Failure or Default         8 (15.1)     0.85 (0.29--2.46)                                   
  Transfer out               7 (20.0)     1.19 (0.35--3.69)                                   
  Died                       9 (17.3)     *ref*                                               

Timely ART provision was defined as within two weeks for patients with a CD4 \<50ecll/μL or missing, and as within eight weeks for all others.

###### 

Healthcare Worker Interview Responses (N=333)

                                                                            N     \%
  ------------------------------------------------------------------------- ----- ------
                                                                                  
  **Cadre of Healthcare Staff Interviewed** (N=333)                               
                                                                                  
  Doctors                                                                   50    15.0
  Nurse                                                                     108   32.4
  Pharmacists                                                               10    3.0
  Lab Scientists                                                            13    3.9
  Community Health Workers                                                  100   30.0
  Medical Records staff                                                     15    4.5
  Counsellors                                                               16    4.8
  Others                                                                    21    6.3
                                                                                  
  **Reported Facility Characteristics**                                           
                                                                                  
  **Has TB diagnostic services (AFB) available** (N=l78)                    175   98.3
                                                                                  
  **TB/HIV service delivery model** (N=312)                                       
  Stand-alone TB facility                                                   133   42.6
  Stand-alone ART facility                                                  54    17.3
  Integrated TB/HIV facility                                                125   40.1
                                                                                  
  **CD4 available at site** (N=240)                                         137   57.1
                                                                                  
  **Distance to referral site for TB diagnosis** (n = 136)                        
  Less than 5 Km                                                            56    41.2
  6--10 Km                                                                  39    28.7
  10--20 Km                                                                 29    21.3
  Over 20 Km                                                                12    8.8
                                                                                  
  **Method of TB patient referral for HIV services** (N= 232)                     
  Physical escort                                                           93    40.1
  Referral slip/directed to ART site                                        89    38.4
  Given an appointment                                                      19    8.2
  Don't know/other                                                          31    13.4
                                                                                  
  **Healthcare Worker TB/HIV Knowledge and Management**                           
                                                                                  
  **Reports past training on TB/HIV** (N=285)                               170   59.6
                                                                                  
  **Reports past training on HIV testing for TB patients** (N=207)          191   92.2
                                                                                  
  **Reports available TB/HIV guidelines** (N= 282)                          238   84.4
                                                                                  
  **Reports available guidelines on HIV testing for TB patients** (N=282)   238   84.4
                                                                                  
  **Identification of PLHIV for TB evaluation** (N=265)                           
  Every patient                                                             83    31.2
  Presumptive TB patients only                                              139   52.5
  Don't know/other                                                          43    16.2
                                                                                  
  **Asks adult TB patients about child contacts** (N=264)                   249   94.3
                                                                                  
  **Interpretation of guidelines for ART in TB/HIV patients** (N=242)             
  ART initiation based on CD4                                               101   41.7
  ART initiation irrespective of CD4                                        94    38.8
  Don't know/other                                                          47    19.4
                                                                                  
  **Interpretation of guidelines for patients with CD4\<50** (N= 236)             
  Immediate within 2 weeks                                                  99    41.9
  Deferment till after 2 months of TB Rx                                    39    16.5
  Initiation based on clinical judgement                                    39    16.5
  Don't know/Other                                                          59    25.0
                                                                                  
  **Opinion on how to improve TB case detection** (N=339)                         
  Implement active TB case finding                                          155   45.7
  Improve on TB contact tracing                                             9     2.7
                                                                                  
  **Opinion on how to ensure TB/HIV patients enroll in care** (N= 221)            
  Practice same day enrollment                                              133   60.2
  Don't know/Other                                                          88    39.8
                                                                                  
  **Opinion on how to ensure ART started within 8 weeks** (N= 215)                
  Given appointment at start of TB                                          86    40.0
  Use of reminders                                                          30    14.0
  Tracked home on missed appointment                                        37    17.2
  Don't know/Other                                                          62    28.8
                                                                                  
  **Opinion on how to ensure TB/HIV patients remain on ART** (N=216)              
  Provide adherence support                                                 141   65.3
  Use of treatment supporter                                                23    10.6
  Don't know                                                                39    18.1
  Other methods                                                             24    11.1
                                                                                  
  **Recommendations for service improvement** (N= 226)                            
                                                                                  
  Referral/proper patient follow up                                         43    19.0
  Counseling and health education                                           87    38.5
  Campaign and awareness                                                    3     1.3
  Capacity building for HCWs                                                28    12.4
  Establishment of same site services                                       5     2.2
  Mixed responses of the above and others                                   64    28.3
